Share on StockTwits

DexCom (NASDAQ:DXCM) VP John Lister sold 3,500 shares of DexCom stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $36.13, for a total value of $126,455.00. Following the completion of the transaction, the vice president now directly owns 115,908 shares in the company, valued at approximately $4,187,756. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of DexCom (NASDAQ:DXCM) traded down 0.03% on Friday, hitting $36.00. The stock had a trading volume of 518,076 shares. DexCom has a 52 week low of $19.93 and a 52 week high of $49.83. The stock’s 50-day moving average is $33.1 and its 200-day moving average is $37.45. The company’s market cap is $2.697 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter last year, the company posted ($0.16) earnings per share. DexCom’s revenue was up 59.1% compared to the same quarter last year. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.

A number of research firms have recently commented on DXCM. Analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $33.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of DexCom from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $38.36.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.